Cited by 288Monoclonal and Polyclonal Antibodies ResearchBiosimilars and Bioanalytical MethodsPharmaceutical studies and practices

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: What have we learned?

Open access

Deng, Rong, Iyer, Suhasini, Theil, Frank-Peter, Mortensen, Deborah L., Fielder, Paul J., Prabhu, Saileta·2011·mAbs

DOI 10.4161/mabs.3.1.13799PMC PMC3038012

Open this paper in CoChat — free account Open PDF

Abstract

The pharmacokinetics (PK) of therapeutic antibodies is determined by target and non-target mediated mechanisms. These antibody-specific factors need to be considered during prediction of human PK based upon preclinical information. Principles of allometric scaling established for small molecules using data from multiple animal species cannot be directly applied to antibodies. Here, different methods for projecting human clearance (CL) from animal PK data for 13 therapeutic monoclonal antibodies (mAbs) exhibiting linear PK over the tested dose ranges were examined: simple allometric scaling (CL versus body weight), allometric scaling with correction factors, allometric scaling based on rule of exponent and scaling from only cynomolgus monkey PK data. A better correlation was obtained between the observed human CL and the estimated human CL based on cynomolgus monkey PK data and an allometric scaling exponent of 0.85 for CL than other scaling approaches. Human concentration-time profiles were also reasonably predicted from the cynomolgus monkey data using species-invariant time method with a fixed exponent of 0.85 for CL and 1.0 for volume of distribution. In conclusion, we expanded our previous work and others and further confirmed that PK from cynomolgus monkey alone can be successfully scaled to project human PK profiles within linear range using simplify allometry and Dedrick plots with fixed exponent.

Integrity signals

Registry

Crossref · 10.4161/mabs.3.1.13799

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Physiological Parameters in Laboratory Animals and Humans
Davies, B., & Morris, T. (1993) · Pharmaceutical Research · doi:10.1023/a:1018943613122 · Cited by 2,930
Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
Wang, W., Wang, E., & Balthasar, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.170 · Cited by 978
The origin of allometric scaling laws in biology from genomes to ecosystems: towards a quantitative unifying theory of biological structure and organization
West, G. B., & Brown, J. H. (2005) · Journal of Experimental Biology · doi:10.1242/jeb.01589 · Cited by 806
To Scale or Not to Scale: The Principles of Dose Extrapolation
Sharma, V., & McNeill, J. H. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00267.x · Cited by 544
Differences in promiscuity for antibody–FcRn interactions across species: implications for therapeutic antibodies
Ober, R. J., Radu, C. G., Ghetie, V. F., & Ward, E. S. (2001) · International Immunology · doi:10.1093/intimm/13.12.1551 · Cited by 502
Population Pharmacokinetics of Therapeutic Monoclonal Antibodies
Dirks, N. L., & Meibohm, B. (2010) · Clinical Pharmacokinetics · doi:10.2165/11535960-000000000-00000 · Cited by 500
Animal Scale-Up
Dedrick, R. L. (1973) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059667 · Cited by 397
Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced Cancer
Agus, D. B., Gordon, M. S., Taylor, C., Natale, R. B., Karlan, B. Y., Mendelson, D. S., Press, M. F., Allison, D. E., Sliwkowski, M. X., Lieberman, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.184 · Cited by 390
Interspecies Pharmacokinetic Scaling and the Evolutionary-Comparative Paradigm
Boxenbaum, H. G. (1984) · Drug Metabolism Reviews · doi:10.3109/03602538409033558 · Cited by 270
Interspecies Scaling: Predicting Clearance of Drugs in Humans. Three Different Approaches
Mahmood, I., & Balian, J. D. (1996) · Xenobiotica · doi:10.3109/00498259609052491 · Cited by 257

Flagged first, then by citations

Show all 24 references

Research works printed but not linked: 1

Deng R, 2007, Prediction of human pharmacokinetics for monoclonal antibody

Sorted by citations

Items 201–288 of 288

A minimal physiologically based pharmacokinetic model to characterize colon TNF suppression and treatment effects of an anti-TNF monoclonal antibody in a mouse inflammatory bowel disease model
Zheng, S., Niu, J., Geist, B. J., Fink, D., Xu, Z., Zhou, H., & Wang, W. (2020) · mAbs · doi:10.1080/19420862.2020.1813962 · Cited by 7
Pharmacokinetics and Toxicokinetics
Schrag, M. L., & Regal, K. A. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-387815-1.00003-4 · Cited by 7
Safety and pharmacokinetics of IBI112, an IL-23 monoclonal antibody, in Chinese healthy volunteers: a first-in-human phase 1 study
He, J., Du, W., Yang, H., Wang, J., Cai, C., Ma, Q., Li, N., Yu, J., Wu, X., Wu, J., et al. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2230122 · Cited by 6
Comparison of Model‐Predicted and Observed Evinacumab Pharmacokinetics and Efficacy in Children Aged < 5 Years With Homozygous Familial Hypercholesterolemia
Bihorel, S., Dingman, R. K., Mendell, J., Norman, K. C., George, R. T., Zhao, X.-Q., Pordy, R. C., Garcia, D., Putnam, W. S., Raghuveer, G., et al. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70017 · Cited by 6
Utilizing PK and PD Biomarkers to Guide the First-in-Human Starting Dose Selection of MTBT1466A: A Novel Humanized Monoclonal Anti-TGFβ3 Antibody for the Treatment of Fibrotic Diseases
Yadav, R., Sukumaran, S., Lutman, J., Mitra, M. S., Halpern, W., Sun, T., Setiadi, A., Neighbors, M., Sheng, X. R., Yip, V., et al. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.07.005 · Cited by 6
Pharmacokinetics and Biodistribution of a Human Monoclonal Antibody to Oxidized LDL in Cynomolgus Monkey Using PET Imaging
Kamath, A. V., Williams, S. P., Bullens, S., Cowan, K. J., Stenberg, Y., Cherry, S. R., Rendig, S. V., Kukis, D. L., Griesemer, C. D., Damico‐Beyer, L. A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045116 · Cited by 6
Contrasting toxicokinetic evaluations and interspecies pharmacokinetic scaling approaches for small molecules and biologics: applicability to biosimilar development
Offman, E. M., & Edginton, A. N. (2012) · Xenobiotica · doi:10.3109/00498254.2012.744113 · Cited by 6
Pharmacokinetic prediction of an antibody in mice based on an in vitro cell-based approach using target receptor-expressing cells
Noguchi, Y., Ozeki, K., & Akita, H. (2020) · Scientific Reports · doi:10.1038/s41598-020-73255-1 · Cited by 6
Leveraging protein language and structural models for early prediction of antibodies with fast clearancePreprint
Mazrooei, P., O’Neil, D., Izadi, S., Chen, B., & Ramanujan, S. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.08.597997 · Cited by 6
Predicting the Pharmacokinetics of T‐Cell Engagers as a Function of Target‐Mediated Drug Disposition
Penney, M., Ippolito, A., Fevola, E., Rata, S., Brown, L., Gutierrez, P. M., & Jones, R. D. O. (2025) · Clinical and Translational Science · doi:10.1111/cts.70384 · Cited by 5
Predicting human pharmacokinetic parameters of drugs using a multi-tissue chip platform integrating liver, kidney, and skeletal muscle microphysiological systems
Sherfey, J. S., Rajan, S. A. P., Nichols, L. M., Parekh, P., Smith, J. T., Gregory, L., Clark, F., Kadar, E. P., Ohri, S., George, B. T., et al. (2026) · Lab on a Chip · doi:10.1039/d6lc00008h · Cited by 5
Cross-Species Extrapolation of Neonatal Fc Receptor (FcRn) Binding Affinity to Predict Monoclonal Antibody Pharmacokinetics in Humans Using Physiologically Based Pharmacokinetic Modeling (PBPK): Are We There Yet?
Benamara, S., Troisi, C., Gattacceca, F., Sjögren, E., Nguyen, L., & Teutonico, D. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00356 · Cited by 5
Monoclonal Antibodies: From Structure to Therapeutic Application
Deng, R., Li, J., Boswell, C. A., Joshi, A., & Li, C. (2024) · Springer eBooks · doi:10.1007/978-3-031-30023-3_8 · Cited by 6
Self-citation
Pharmacokinetics and Pharmacodynamics of Therapeutic Proteins and Nucleic Acids
Meibohm, B. (2024) · Springer eBooks · doi:10.1007/978-3-031-30023-3_6 · Cited by 5
Pharmacokinetic models for first-in-human dose selection of immune-activating products in oncology
Saber, H., Thompson, M. D., & Leighton, J. K. (2024) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2024.105616 · Cited by 5
Predicting pharmacokinetic profile of therapeutic antibodies after iv injection from only the data after sc injection in cynomolgus monkey
Haraya, K., Tachibana, T., & Nezu, J. (2016) · Xenobiotica · doi:10.1080/00498254.2016.1174792 · Cited by 5
Pharmacokinetics and Pharmacodynamics of CD4-Anchoring Bi-Functional Fusion Inhibitor in Monkeys
Liu, X., Ou, Y. C., Zhang, J., Ahene, A. B., Clark, D., Hsieh, S., Cooper, M., & Ji, C. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1203-4 · Cited by 5
Pharmacokinetic and Pharmacodynamic‐Based Drug Interactions for Therapeutic Proteins
Lü, D., Girish, S., Theil, F., & Joshi, A. (2013) · Pharmaceutical Sciences Encyclopedia · doi:10.1002/9780470571224.pse473 · Cited by 5
Self-citation
Model-Based Interspecies Scaling for Predicting Human Pharmacokinetics of CB 4332, a Complement Factor I Protein
Alsoud, R. A., Moan, N. L., Holten-Andersen, L., Knudsen, T., Lennernäs, H., & Simonsson, U. S. H. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2024.06.022 · Cited by 4
A Simple Method for the Prediction of Human Concentration–Time Profiles and Pharmacokinetics of Antibody–Drug Conjugates (ADC) from Rats or Monkeys
Mahmood, I. (2022) · Antibodies · doi:10.3390/antib11020042 · Cited by 4
Predicting Human Bioavailability of Subcutaneously Administered Monoclonal Antibodies Using Non-human Primate Linear Clearance and Antibody Isoelectric Point
Zou, P. (2023) · The AAPS Journal · doi:10.1208/s12248-023-00818-1 · Cited by 4
A Minimal PBPK/PD Model with Expansion-Enhanced Target-Mediated Drug Disposition to Support a First-in-Human Clinical Study Design for a FLT3L-Fc Molecule
Hosseini, I., Fleisher, B., Getz, J. A., Decalf, J., Kwong, M., Ovacik, M., Bainbridge, T. W., Moussion, C., Rao, G. K., Gadkar, K. G., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16050660 · Cited by 4
Comprehensive population pharmacokinetic modelling of sugemalimab, an anti‐programmed death‐ligand 1 (PD‐L1) human monoclonal antibody, in patients with solid tumours or lymphomas across multiple Phase I–III studies
Wang, K., Pan, C., Xu, F., Tse, A. N., & Sheng, Y. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16276 · Cited by 4
Novel Biopharmaceuticals
Marian, M., & Seghezzi, W. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394810-6.00004-6 · Cited by 4
Pharmacokinetic Time Course Scaling of a Subcutaneously Administered Pegylated Peptide Conjugate for a First-in-Human Investigation
Offman, E. M., & Edginton, A. N. (2016) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-016-0322-9 · Cited by 4
Anti–Lymphocyte Antigen 6 Complex, Locus E-Seco-Cyclopropabenzindol-4-One-Dimer Antibody-Drug Conjugate That Forms Adduct with α1-Microglobulin Demonstrates Slower Systemic Antibody Clearance and Reduced Tumor Distribution in Animals
Yip, V., Figueroa, I., Latifi, B., Masih, S., Ng, C., Leipold, D., Kamath, A. V., & Shen, B. (2020) · Drug Metabolism and Disposition · doi:10.1124/dmd.120.000145 · Cited by 4
Population pharmacokinetics of raxibacumab in healthy adult subjects
Oosterholt, S. P., & Pasqua, O. E. D. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14894 · Cited by 4
Second generation CD2-targeting LFA-3 fusion protein SBT115301 to restore immune homeostasis in autoimmune disease
Lebrec, H. N., Bui, J., Clingan, J. M., Do, J., Dubovsky, J. A., Dragone, L. L., Gibiansky, E., Lam, W. Y., Matsuda, K. C., Mihalcik, L., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112447 · Cited by 3
Application of Mechanistic Pharmacokinetic–Pharmacodynamic Modeling toward the Development of Biologics
Singh, P., Tiwari, A., Abraham, A. K., & Zutshi, A. (2015) · CRC Press eBooks · doi:10.1201/b19023-7 · Cited by 3
Dose Finding in Single Dose Studies by Allometric Scaling
Lu, Z., Kaspera, R., Naritomi, Y., & Wang, T. (2020) · Springer eBooks · doi:10.1007/978-3-319-68864-0_3 · Cited by 3
A novel semi‐mechanistic tumor growth fraction model for translation of preclinical efficacy of anti‐glypican 3 antibody drug conjugate to human
Singh, R., Kozhich, A. T., Pan, C., Lee, F. Y., Cardarelli, P. M., Vangipuram, R., Iyer, R., & Marathe, P. (2020) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2249 · Cited by 3
Translational pharmacokinetic and pharmacodynamic modelling of the anti-ADAMTS-5 NANOBODY® (M6495) using the neo-epitope ARGS as a biomarker
Pereira, J. N. S., Ottevaere, I., Serruys, B., Guehring, H., Ladel, C. H., & Lindemann, S. (2024) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-024-09958-z · Cited by 3
Intravitreal Concentrations of a Near-Infrared Fluorescence–Labeled Biotherapeutic Determined In Situ Using Confocal Scanning Laser Ophthalmoscopy
Basile, A. S., Glazier, G., Lee, A. R., Jiang, L., Johnson, T. R., Shields, M. J., Vézina, M., & Doppalapudi, V. R. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-7790 · Cited by 3
Monoclonal Antibodies: From Structure to Therapeutic Application
Deng, R., Boswell, C. A., Putnam, W. S., Tang, M. T., Garg, A., Li, C., Chung, S., & Girish, S. (2019) · Springer eBooks · doi:10.1007/978-3-030-00710-2_8 · Cited by 3
Self-citation
Use of PK / PD Knowledge in Guiding Bispecific Biologics Research and Development
Baumann, A., Prabhu, S., & Kanodia, J. (2015) · Wiley eBooks · doi:10.1002/9780470571224.pse562 · Cited by 3
Self-citation
Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions
Mallillin, M. C., Silva, D. A., Miller, N. A., Zhao, S., Salami, M., Löbenberg, R., & Davies, N. M. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18070824 · Cited by 2
Pharmacokinetic-pharmacodynamic modeling of a highly potent and broadly neutralizing anti-CD4 trimeric nanobody to inhibit HIV-1 infection
Fan, X., Cao, K., Wu, X., & Yan, X. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.00805-25 · Cited by 2
Model-based assessment of VRC07-523LS dosing in infants through population pharmacokinetic -pharmacodynamic modelling in adults and infants
Huynh, D., Nikanjam, M., Cunningham, C. K., McFarland, E. J., Muresan, P., Perlowski, C., Yin, D. E., Moye, J., Spiegel, H., Gama, L., et al. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf449 · Cited by 2
A cell based assay for evaluating binding and uptake of an antibody using hepatic nonparenchymal cells
Noguchi, Y., Ozeki, K., Takesue, H., & Akita, H. (2021) · Scientific Reports · doi:10.1038/s41598-021-87912-6 · Cited by 2
A Quantitative Prediction Method for the Human Pharmacokinetics of Fc-Fusion Proteins
Yokoyama, M., Suzuki, E., Oitate, M., & Watanabe, N. (2023) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-023-00845-5 · Cited by 2
A mechanistic PK/PD model of AZD0171 (anti‐LIF) to support Phase II dose selection
Shahraz, A., Penney, M., Candido, J. B., Opoku‐Ansah, G., Neubauer, M., Eyles, J. E., Ojo, O. O., Liu, N., Luheshi, N., Phipps, A., et al. (2024) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13204 · Cited by 2
Nonclinical Development of Multi-targeting Biopharmaceuticals
Prell, R. A., Lee, D. W., Halpern, W., & Connor, A. V. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394810-6.00014-9 · Cited by 2
A Global Perspective on First-in-Man Dose Selection: Oncology and Beyond
Zou, P., Lee, S., Li, M., Yu, L. X., & Sun, D. (2016) · Springer eBooks · doi:10.1007/978-3-319-39053-6_3 · Cited by 2
Prediction of Human Pharmacokineticsfor Protein‐Based Biologic Therapeutics
Han, C., & Mayer, C. L. (2015) · Wiley eBooks · doi:10.1002/9780470571224.pse543 · Cited by 2
Dose Finding in Single Dose Studies by Allometric Scaling
Lu, Z., Kaspera, R., Naritomi, Y., & Wang, T. (2017) · Springer eBooks · doi:10.1007/978-3-319-56637-5_3-1 · Cited by 1
A Non-radiometric Approach to Determine Tissue Vascular Blood Volume in Biodistribution Studies
Salimi-Moosavi, H., & Soto, M. (2022) · The AAPS Journal · doi:10.1208/s12248-022-00770-6 · Cited by 1
Prediction of human serum concentration–time profiles of therapeutic monoclonal antibodies using common marmosets ( Callithrix jacchus ): initial assessment with canakinumab, adalimumab, and bevacizumab
Tajiri, A., Matsumoto, S., Maeda, S., Soga, T., Kagiyama, K., Ikeda, H., Fukasawa, K., Miyata, A., & Kamimura, H. (2024) · Xenobiotica · doi:10.1080/00498254.2024.2371921 · Cited by 1
A systematic review of allometric scaling exponents for IgG mAbs
Rowland, S. P., Nixon, E., Mohan, K., Wang, Q., & Yates, J. W. T. (2024) · Xenobiotica · doi:10.1080/00498254.2024.2383925 · Cited by 2
Integrative and Emerging Models in Antibody Research: A Comprehensive Review
Devasani, J. R., Guntuku, G., sarabu, P., Muthyala, M. K. K., Palla, M. S., & Volety, M. S. (2025) · Antibody Therapeutics · doi:10.1093/abt/tbaf018 · Cited by 2
High-dose biologics and bioconjugates delivery: Integrating molecular optimization with device design and routes of administration
Budhavaram, N. K., Duffy, K. H., Abouzeid, A. H., Bharadwaj, R., Shrestha, N., Echeverri, E. S., Mitchener, C., & Subramony, J. A. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115893 · Cited by 1
A novel scaling approach for human pharmacokinetic prediction of antibody-drug conjugates using minimal nonclinical data: Integration of monkey PK and in vitro data
Nakayama, S., Torimoto, N., Kudo, T., & Ito, K. (2026) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2026.101543 · Cited by 1
Preclinical pharmacokinetics of novel MYDGF for human PK and dose prediction
Myzithras, M., Wei, W., Bigwarfe, T., Chen, L., Gupta, P., Li, H., & Pekcec, A. (2026) · Bioanalysis · doi:10.1080/17576180.2026.2682870 · Cited by 1
Semi-mechanistic population pharmacokinetic modeling of DZIF-10c, a neutralizing antibody against SARS-Cov-2: predicting systemic and lung exposure following inhaled and intravenous administration
Kurup, S., de Mendizábal, N. V., Becker, S., Bolella, E., Sousa, D. D., Fätkenheuer, G., Gruell, H., Klein, F., Malin, J. J., Schmid, U., et al. (2024) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-024-09947-2 · Cited by 1
Population‐Based Modeling to Predict Human PK / PD of TAK ‐500, an Anti‐CCR2 Antibody–Drug Conjugate for First‐in‐Human Study in Cancer Patients
Saravanakumar, A., Deng, R., Dong, L., Haridas, S., Xia, C. Q., Appleman, V. A., Abu‐Yousif, A. O., Piatkov, K. I., & Wang, H. (2026) · Clinical and Translational Science · doi:10.1111/cts.70522 · Cited by 1
Self-citation
Optimizing bevacizumab exposure in atezolizumab-based therapy for unresectable hepatocellular carcinoma: A nationwide real-world study
Aoe, K., Tada, T., Hiraoka, A., Matono, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., et al. (2026) · Hepatology · doi:10.1097/hep.0000000000001781 · Cited by 1
Human Dose and Pharmacokinetic Predictions for Biologics at Boehringer Ingelheim: A Retrospective Analysis
Grempler, R., Ahlberg, J., Germovsek, E., Gupta, P., Li, H., Pilvankar, M., Sharma, A., Stopfer, P., & Hansel, S. B. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02710-y · Cited by 1
Translate Pharmacokinetics of PD-1/PD-L1 Monoclonal Antibodies from Cynomolgus Monkey to Human: Comparison of Different Approaches
Chen, W., Wang, L., Ruan, Z., Lou, H., & Jiang, B. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2024.07.003 · Cited by 1
Therapeutic antibody development—Remington chapter
Geist, B. J., Zheng, S., & Xu, Y. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820007-0.00024-6 · Cited by 1
Improving priors for human monoclonal antibody linear pharmacokinetic parameters by using half-lives from non-human primates
Shivva, V., Fink, M., & Lowe, P. J. (2021) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-020-09731-y · Cited by 1
Pre-clinical strategies and safety issues in developing therapeutic monoclonal antibodies
Chamberlain, P. (2011) · New Biotechnology · doi:10.1016/j.nbt.2011.03.017 · Cited by 1
Challenges in the Pharmacokinetics of Therapeutic Proteins
Limothai, W. (2015) · doi:10.21007/etd.cghs.2015.0184 · Cited by 1
BROOKHAVEN REACTOR GAMMA FLUX BY CALORIMETRY
Carroll, J. G., & Bolt, R. O. (1958) · OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) · Cited by 1
Fixed Dosing versus Body‐Size‐Based Dosing for Therapeutic Biologics—A Clinical Pharmacology Strategy
Wang, D. D., Hoffman, J., & Parivar, K. (2015) · Pharmaceutical Sciences Encyclopedia · doi:10.1002/9780470571224.pse544
Drug Development Strategies for Therapeutic Biologics: Industry Perspectives
Yuraszeck, T. M., & Gibbs, M. A. (2015) · Wiley eBooks · doi:10.1002/9780470571224.pse559
ADME for Therapeutic Biologics: What Can We Leverage from Great Wealth of ADME Knowledge and Research for Small Molecules
Wang, W., & Prueksaritanont, T. (2015) · Wiley eBooks · doi:10.1002/9780470571224.pse536
Role of Lymphatic System in Subcutaneous Absorption of Therapeutic Proteins
Lin, J. H., & Wang, W. (2015) · Pharmaceutical Sciences Encyclopedia · doi:10.1002/9780470571224.pse541
Application of Minimal Anticipated Biological Effect Level ( MABEL ) in Human Starting Dose Selection for Immunomodulatory Protein Therapeutics – Principles and Case Studies
Wang, H., Yang, Z., & Shi, R. (2019) · Wiley eBooks · doi:10.1002/9781119289234.ch4
Biotherapeutics ADME and PK/PD Principles
Yadav, D. B., Gadkar, K. G., & Figueroa, I. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821044-4.00009-1
PBPK MODELING OF BIOTHERAPEUTICS
Peters, S. A. (2021) · Wiley eBooks · doi:10.1002/9781119497813.ch8
Protein Therapeutics
Leach, M. W., & Hammerman, K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821047-5.00024-5
Preclinical to Clinical Translation of Antibody Drug Conjugates Using a Quantitative Systems Pharmacology (QSP) Model: A Case Study with Disitamab VedotinPreprint
Li, Q., Wang, L., Wu, B., Ma, X., Zhao, G., Liu, Z., Wang, J., Liu, H., & Jiang, J. (2024) · Research Square · doi:10.21203/rs.3.rs-4543078/v1
Novel biopharmaceuticals: Pharmacokinetics, pharmacodynamics, and bioanalytics
Bosgra, S., & Gupta, M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13344-2.00013-4
Pharmacokinetics of Therapeutic Antibodies and Derivatives
Chen, E. P. (2025) · Wiley eBooks · doi:10.1002/9781119650263.ch08
PKPD modeling and in silico models
Pehrson, R., Winiwarter, S., Subramanian, V., Mogemark, M., & Miljković, F. N. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00022-4
Selection of isatuximab dosing regimen in pediatric patients with leukemia using population pharmacokinetics
Brillac, C., Sémiond, D., Oprea, C., Baruchel, A., Zwaan, C. M., & Nguyen, L. (2025) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-025-04832-2
Additional file 3 of hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers
Martinelli, I., Modica, C., Chiriaco, C., Basilico, C., Hughes, J. M., Corso, S., Giordano, S., Comoglio, P. M., & Vigna, E. (2022) · Figshare · doi:10.6084/m9.figshare.19451301
Additional file 2 of hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers
Martinelli, I., Modica, C., Chiriaco, C., Basilico, C., Hughes, J. M., Corso, S., Giordano, S., Comoglio, P. M., & Vigna, E. (2022) · Figshare · doi:10.6084/m9.figshare.19451298
Additional file 1 of hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers
Martinelli, I., Modica, C., Chiriaco, C., Basilico, C., Hughes, J. M., Corso, S., Giordano, S., Comoglio, P. M., & Vigna, E. (2022) · Figshare · doi:10.6084/m9.figshare.19451295
Intrathoracic 90Y-NZ-16 therapy improves efficacy and reduces toxicity in pleural mesothelioma mice
Sudo, H., Tsuji, A. B., Sugyo, A., Kaneko, M. K., Kato, Y., & Higashi, T. (2026) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000002112
Population Pharmacokinetic Analysis of Vixarelimab in Healthy Volunteers and Patients With Chronic Pruritic Conditions
Tang, F., Dang, S., Arjomandi, A., Pan, L., Hsu, J., Kshirsagar, S. A., & Kassir, N. (2026) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70230
Industry Practices in Monoclonal Antibody Tissue Biodistribution Assessment: An IQ Consortium Cross-Industry Survey of Current Approaches and Emerging Trends
Tang, H., McCoy, M., Leonard, A., Mohan, K., Sane, R., Guan, C., Kullolli, M., & Koep, K. (2026) · The AAPS Journal · doi:10.1208/s12248-026-01216-z
抗体の薬物動態評価を目的とした新規in vitro細胞評価系の開発
野口, 裕. (n.d.) · Institutional Repositories DataBase (IRDB) · doi:10.20776/900121103
A comprehensive evaluation of the human Tg32 and Tg276 FcRn transgenic mouse and non-human primate models for predicting antibody pharmacokinetics in human
Gajewska, M., Kiffe, M., Calonder, C., Engelhardt, V., Miralbell, C. P., Gonzalo-Gil, E., Christianson, G. J., BETHUR, N., & Flora, A. (2026) · mAbs · doi:10.1080/19420862.2026.2668888
Prediction of Human Serum Concentration–Time Profiles of Golimumab and Ustekinumab Using Pharmacokinetic Data From Common Marmosets With Assessment of Anti‐Drug Antibodies
Tajiri, A., Matsumoto, S., Furukawa, N., Kagiyama, K., Ikeda, H., Fukasawa, K., & Takano, H. (2026) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.70035
Human Pharmacokinetic Prediction of Antibody‐Drug Conjugates Using Human FcRn Transgenic Mice
Nakagawa, K., & Haraya, K. (2026) · Clinical and Translational Science · doi:10.1111/cts.70692
Modeling effective doses of therapeutic antibodies targeting clustered surface receptors
Vanamee, É. S., Grant, J., Rao, S., Adams, L., Kühtreiber, W. M., & Faustman, D. L. (2026) · Scientific Reports · doi:10.1038/s41598-026-65275-0
Pharmacokinetic modeling frameworks for complex antibody-drug conjugates analytes: clinical pharmacology considerations
Kumar, D., Verma, A., & Trivedi, N. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118364
Preclinical pharmacokinetic modeling and clinical translation of SIG001, a novel anti-cancer therapeutic antibody targeting on cancer-derived sialylated IgG
Yao, Q., Liu, C., Zhang, S., Liu, Y., Zhou, Y., & Qiu, X. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1904283

Authors: Deng, R., Iyer, S., Theil, F.-P., Mortensen, D. L., Fielder, P. J., & Prabhu, S.
Affiliations: Genentech (US)
Corresponding author: Deng, Rong
ORCID: Deng, Rong
Iyer, Suhasini
Theil, Frank-Peter
Prabhu, Saileta
Venue: mAbs
Publisher: Informa UK Limited
Published: 2011-01
Volume: 3
Issue: 1
Pages: 61-66
ISSN: 1942-0862 (ISSN-L)
1942-0870
DOI: 10.4161/mabs.3.1.13799
PMC: PMC3038012
OpenAlex: W1555185942
Cited by: 285
References: 24
Citations by year: 2026: 16 · 2025: 13 · 2024: 25 · 2023: 10 · 2022: 17 · 2021: 27 · 2020: 15 · 2019: 19 · 2018: 18 · 2017: 19 · 2016: 23 · 2015: 24 · 2014: 14 · 2013: 21 · 2012: 14
FWCI: 14.18
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by-nc
Locations: mAbs (publishedVersion, cc-by-nc)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Genentech
Topics: Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
Keywords: therapeutic monoclonal antibodies, human pharmacokinetics, allometric scaling, clearance prediction, Macaca fascicularis, volume of distribution
MeSH terms: Algorithms, Animals, Antibodies, Monoclonal, Drug Evaluation, Preclinical, Humans, Macaca fascicularis, Metabolic Clearance Rate, Models, Biological, Species Specificity, Mice, Rats, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: What have we learned?

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks